24-Week Clinical Trial Finds No Evidence of Liver or Kidney Injury with Standardised Ashwagandha Root Extract

A large multicentre, randomised, double-blind, placebo-controlled clinical trial published in Frontiers in Medicine evaluated the prolonged use of a standardised Ashwagandha root extract over 24 weeks among 1,200 vaccinated adults. Conducted by a multidisciplinary team of researchers from nine institutions, including the Central Council for Research in Ayurvedic Sciences (CCRAS), the study found that daily administration of 500 mg of the extract was well tolerated, showing no evidence of treatment-related liver or kidney injury. Furthermore, the trial reported that the extract did not interfere with vaccine-induced immunity following COVISHIELD vaccination.